Molecular Docking and Virtual Screening of Natural Compounds as Potential Anti-Glioblastoma Drugs

Nico Berlinson Fernando, Agus Kartono, Setyanto Tri Wahyudi

Abstract


Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor. Fibroblast growth factor 2 (FGF2) is essential in normal neurodevelopment and promotes glioma growth and vascularization. This study aims to identify the binding sites of FGF2 protein receptors using molecular docking and virtual screening with natural compounds, and to determine the free binding energy between FGF2 protein and herbal active compounds from Indonesian plants. This research includes virtual screening with molecular docking using Vina on 1496 Indonesian herbal compounds, docking with Autodock4.2.6, and analysis of the Autodock4.2.6 docking results using Ligplot+. The amino acids derived from the FGF2 protein bind well to each of the FGFR 1-4 receptors. In the virtual screening, the synthetic compound Temozolomide had docking scores in the range (-4.4) to (-5.0), while compounds from Indonesian herbal plants had docking scores in the range (-6.8) to (-8.1). Hydrogen and hydrophobic interactions occur between the FGF2 receptor and selected herbal compounds. This shows the interaction is stable. These natural compounds will inhibit FGF2 binding to other receptors, thereby inducing apoptosis in FGF2. The results of blind docking show that the binding sites are similar, indicating good accuracy. In summary, Pyranoamentoflavone compounds found in nyamplung (Calophyllum Inophyllum), 5,3',5'-Trihydroxy-6,7,4'-trimethoxyflavone in kemuning (Murura Paniculata), and Sotetsuflavone in jamb antidote (Cycas Revoluta) have good potential as an FGF2 inhibitor as an anti-cancer drug for Glioblastoma.

Full Text:

PDF

References


Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu Sa, Capac CM, et al. Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies—oncotarget 2016; 7:44735-44762.

Bian XW, Du LL, Shi JQ, Cheng YS, Liu FX. Correlation of bFGF, FGFR-1, and VEGF expression with vascularity and malignancy of human astrocytomas. Anal Quant Cytol Histol 2000; 22(3):267-274.

Cheng F, Guo D. MET in glioma: signaling pathways and targeted therapies. Experimental & Clinical Cancer Research 2019; 270(38):1-13.

Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): findings of a multicenter Australian study. Surg Neurol Int 2011; 2:176.

Haley EM, Kim Y. The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells is studied in vitro culture. Cancer Let 2014; 346(1):1-5.

Hetényi C, Spoel DVD. Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Letters 2006; 580(5):1447-1450.

Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. J Med Life 2019; 2(4):386-393.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60(5):277-300.

Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009; 9:639.

Markiewicz-Żukowska et al. Propolis changes the anticancer activity of temozolomide in the U87MG human glioblastoma cell line. BMC Complementary and Alternative Medicine 2013; 13:50.

Media. Brain cancer. Cancer [Internet]. [downloaded 2020 Apr 14]. Available at: https://kankere.com/article/content/kanker-otak-13.

Mukesh B, Rakesh K. Molecular Docking: A Review. International Journal of Research in Ayurveda and Pharmacy 2011; 2:1746–1751.

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. NeuroOncol 2015; 17(4): iv1-iv62.

Perry MC, Demeule M, Regina A, Moumdjian R, Beliveau R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 2010; 54(8):1192-1201.

Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Stem Cells 2009; 4(6):568-580.

Syahputra G. Docking Simulation of Curcumin Compounds and Their Analogs as Inhibitors of 12-Lipoxygenase Enzymes. Thesis 2014; Bogor (ID): IPB University.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2011; 31(2):455-461.

Vengoji R, Macha MA, Batra SK, Shonka NA. Natural products: a hope for glioblastoma patients. Oncotarget 2018; 31(9):22194-22219.

Yang L, Wang Y, Guo H, Guo M. Synergistic anti-cancer effects of icariin and temozolomide in glioblastoma. Cell Biochem Biophysics 2015; 71(3):1379-85.

Zhu P, Du XL, Lu G, Zhu JJ. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget 2017; 8(27):44015-44031.




DOI: http://dx.doi.org/10.20527/jstk.v20i2.25978

Article Metrics

Abstract view : 34 times
PDF - 29 times

Refbacks

  • There are currently no refbacks.


Department of Chemistry
Faculty of Mathematics and Natural Sciences
Universitas Lambung Mangkurat
Jl. A. Yani KM. 36 Banjarbaru 70714, Indonesia
Email: [email protected]
ISSN: 1411-1616 E-ISSN: 2549-8215

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License .